hrcak mascot   Srce   HID

Libri Oncologici : Croatian Journal of Oncology, Vol.45 No.2-3 Prosinac 2017.

Pregledni rad

Advances in melanoma immunotherapy

Nina Dabelić ; Department of Oncology and Radiotherapy, Reff eral Center for Melanoma of Ministry of Health of Republic of Croatia, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Jasmina Marić Brozić ; Department of Oncology and Radiotherapy, Reff eral Center for Melanoma of Ministry of Health of Republic of Croatia, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Nikola Đaković ; Department of Oncology and Radiotherapy, Reff eral Center for Melanoma of Ministry of Health of Republic of Croatia, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ante Bolanča ; Department of Oncology and Radiotherapy, Reff eral Center for Melanoma of Ministry of Health of Republic of Croatia, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

Puni tekst: engleski, pdf (173 KB) str. 46-51 preuzimanja: 109* citiraj
APA 6th Edition
Dabelić, N., Marić Brozić, J., Đaković, N. i Bolanča, A. (2017). Advances in melanoma immunotherapy. Libri Oncologici, 45 (2-3), 46-51. Preuzeto s https://hrcak.srce.hr/192125
MLA 8th Edition
Dabelić, Nina, et al. "Advances in melanoma immunotherapy." Libri Oncologici, vol. 45, br. 2-3, 2017, str. 46-51. https://hrcak.srce.hr/192125. Citirano 17.10.2018.
Chicago 17th Edition
Dabelić, Nina, Jasmina Marić Brozić, Nikola Đaković i Ante Bolanča. "Advances in melanoma immunotherapy." Libri Oncologici 45, br. 2-3 (2017): 46-51. https://hrcak.srce.hr/192125
Harvard
Dabelić, N., et al. (2017). 'Advances in melanoma immunotherapy', Libri Oncologici, 45(2-3), str. 46-51. Preuzeto s: https://hrcak.srce.hr/192125 (Datum pristupa: 17.10.2018.)
Vancouver
Dabelić N, Marić Brozić J, Đaković N, Bolanča A. Advances in melanoma immunotherapy. Libri Oncologici [Internet]. 21.12.2017. [pristupljeno 17.10.2018.];45(2-3):46-51. Dostupno na: https://hrcak.srce.hr/192125
IEEE
N. Dabelić, J. Marić Brozić, N. Đaković i A. Bolanča, "Advances in melanoma immunotherapy", Libri Oncologici, vol.45, br. 2-3, str. 46-51, prosinac 2017. [Online]. Dostupno na: https://hrcak.srce.hr/192125. [Citirano: 17.10.2018.]

Sažetak
Melanoma is considered to be the most immunogenic malignant tumour. This fact is recognized for many years, and certain forms of immunotherapy have been used in melanoma therapy for a considerable time.
Treatment options for patients with metastatic melanoma have changed dramatically in the past 5 years, with the FDA approval of eight new therapeutic agents (immunotherapies and targeted therapies). During this period, melanoma immunotherapy has transitioned from cytokine-based treatment to antibody-mediated blockade of the cytotoxic Tlymphocyteassociated antigen4 (CTLA4) and, recently, the programmed cell-death protein 1 (PD1) immune checkpoints. These changes in the treatment options have dramatically improved patient outcomes, with the median overall survival of patients with metastatic melanoma increasing from approximately 9 months before 2011 to at least 2 years, and probably longer.
Various types of immunotherapy, like pembrolizumab, nivolumab, ipilimumab, combined therapy with nivolumab and ipilimumab, and T-VEC, have been established in recent years as the standard-of-care treatment for metastatic melanoma patients.

Ključne riječi
immunotherapy; melanoma; checkpoint inhibitors; oncolytic vaccines

Hrčak ID: 192125

URI
https://hrcak.srce.hr/192125

[hrvatski]

Posjeta: 148 *